Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a significant stock price increase, attributed to the announcement of early clinical research results for three CDK inhibitors to be presented at the 2025 ESMO annual meeting [1] Group 1: Stock Performance - The stock price of Tongyuan Kang Pharmaceutical-B rose nearly 7% in the morning session and is currently up 5.82%, trading at HKD 15.08 with a transaction volume of HKD 73.088 million [1] Group 2: Clinical Research Announcements - The company announced that three CDK inhibitors, TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i), will have their early clinical research results presented as posters at the 2025 ESMO annual meeting scheduled for October 17-21 in Berlin, Germany [1] - Additionally, the company’s drug, Aidiotini Tablets (TY-9591), targeting brain metastases in non-small cell lung cancer, has garnered significant attention following its key Phase II clinical trial results presented at the World Lung Cancer Conference in September 2025 [1] Group 3: Regulatory Milestones - Aidiotini Tablets, a highly selective small molecule inhibitor developed for classic EGFR mutations, completed patient enrollment of 224 cases for conditional approval by November 2024 and is expected to submit a Pre-NDA application in April 2025, with a formal conditional NDA submission anticipated in Q4 2025 [1]

Core Insights - Company announced early clinical research results for three drugs in the cell cycle protein-dependent kinase inhibitor (CDKi) field, namely TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - Results were presented in poster format at the European Society for Medical Oncology (ESMO) annual meeting, a significant event in the oncology field [1] Company Developments - The company is focusing on the development of CDKi drugs, indicating a strategic emphasis on this therapeutic area [1] - The ESMO 2025 annual meeting will take place from October 17-21, 2025, in Berlin, Germany, highlighting the company's engagement with leading experts in oncology [1]

Core Viewpoint - The company announced early clinical research results for three cell cycle protein-dependent kinase inhibitors (CDKis) at the European Society for Medical Oncology (ESMO) annual meeting, highlighting its strategic focus in this area [1] Group 1: Clinical Research - The three CDK inhibitors presented are TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - The results were showcased in poster format at the ESMO 2025 annual meeting, which is a significant event in the oncology field [1] Group 2: Event Details - The ESMO 2025 annual meeting is scheduled to take place from October 17-21, 2025, in Berlin, Germany [1] - This meeting is recognized as one of the most influential academic gatherings in oncology, attracting top experts and scholars [1]